| Health / Medical Topics |
gp100:17-25 Peptide
A synthetic peptide vaccine consisting of amino acids 17 through 25 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with gp100_17-25 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for gp100, resulting in decreased tumor growth. (NCI Thesaurus)
YOU MAY ALSO LIKE
A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific…
A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum…
Tumor infiltrating lymphocytes (TIL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the…
Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to…
Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a…
A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic…
